Literature DB >> 29339951

Benefits, Concerns, and Future Directions of Biosimilars in Inflammatory Bowel Disease.

Brian Feagan1.   

Abstract

Year:  2017        PMID： 29339951      PMCID： PMC5763561     

Source DB:  PubMed          Journal:  Gastroenterol Hepatol (N Y)        ISSN： 1554-7914


× No keyword cloud information.
  6 in total

1.  Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial.

Authors:  Kristin K Jørgensen; Inge C Olsen; Guro L Goll; Merete Lorentzen; Nils Bolstad; Espen A Haavardsholm; Knut E A Lundin; Cato Mørk; Jørgen Jahnsen; Tore K Kvien
Journal:  Lancet       Date:  2017-05-11       Impact factor: 79.321

Review 2.  Biosimilars in IBD: hope or expectation?

Authors:  Krisztina B Gecse; Reena Khanna; Gijs R van den Brink; Cyriel Y Ponsioen; Mark Löwenberg; Vipul Jairath; Simon P L Travis; William J Sandborn; Brian G Feagan; Geert R A M D'Haens
Journal:  Gut       Date:  2013-03-16       Impact factor: 23.059

Review 3.  The challenge of indication extrapolation for infliximab biosimilars.

Authors:  Brian G Feagan; Denis Choquette; Subrata Ghosh; Dafna D Gladman; Vincent Ho; Bernd Meibohm; Guangyong Zou; Zhenhua Xu; Gopi Shankar; David C Sealey; Anthony S Russell
Journal:  Biologicals       Date:  2014-06-21       Impact factor: 1.856

Review 4.  The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?

Authors:  Pieter Hindryckx; Niels Vande Casteele; Gregor Novak; Reena Khanna; Geert D'Haens; William J Sandborn; Silvio Danese; Vipul Jairath; Brian G Feagan
Journal:  J Crohns Colitis       Date:  2018-01-05       Impact factor: 9.071

5.  A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: the PLANETRA study.

Authors:  Dae Hyun Yoo; Pawel Hrycaj; Pedro Miranda; Edgar Ramiterre; Mariusz Piotrowski; Sergii Shevchuk; Volodymyr Kovalenko; Nenad Prodanovic; Mauricio Abello-Banfi; Sergio Gutierrez-Ureña; Luis Morales-Olazabal; Michael Tee; Renato Jimenez; Omid Zamani; Sang Joon Lee; HoUng Kim; Won Park; Ulf Müller-Ladner
Journal:  Ann Rheum Dis       Date:  2013-05-16       Impact factor: 19.103

6.  A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study.

Authors:  Won Park; Pawel Hrycaj; Slawomir Jeka; Volodymyr Kovalenko; Grygorii Lysenko; Pedro Miranda; Helena Mikazane; Sergio Gutierrez-Ureña; MieJin Lim; Yeon-Ah Lee; Sang Joon Lee; HoUng Kim; Dae Hyun Yoo; Jürgen Braun
Journal:  Ann Rheum Dis       Date:  2013-05-16       Impact factor: 19.103
  6 in total
  1 in total

1.  Letter to the Editor Regarding "The Challenges of Switching Therapies in an Evolving Multiple Biosimilars Landscape: A Narrative Review of Current Evidence".

Authors:  Barbara Finck; Robert B Geller; Paul Walden
Journal:  Adv Ther       Date:  2021-04-29       Impact factor: 3.845
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.